Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice

Hypertension

Volumn 46, Issue 2, 2005, Pages 441-447

  Nakanishi, Michio ^a   Saito, Yoshihiko ^b   Kishimoto, Ichiro ^a,e   Harada, Masaki ^a   Kuwahara, Koichiro ^a   Takahashi, Nobuki ^a   Kawakami, Rika ^a   Nakagawa, Yasuaki ^a   Tanimoto, Keiji ^a   Yasuno, Shinji ^a   Usami, Satoru ^a   Li, Yuhao ^a   Adachi, Yuichiro ^a   Fukamizu, Akiyoshi ^c   Garbers, David L ^d   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Coronary artery disease; Hypertrophy; Receptors, angiotensin; Remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; BRAIN NATRIURETIC PEPTIDE; GUANYLATE CYCLASE; HYDRALAZINE; MESSENGER RNA; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAUSE OF DEATH; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EXPERIMENTAL MODEL; GENE EXPRESSION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; HISTOLOGY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SODIUM EXCRETION; SURVIVAL RATE; URINE VOLUME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CAUSE OF DEATH; DIURESIS; ECHOCARDIOGRAPHY; FIBROSIS; GUANYLATE CYCLASE; HYDRALAZINE; MALE; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIUM; NATRIURESIS; NATRIURETIC PEPTIDE, BRAIN; ORGAN SIZE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RNA, MESSENGER; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 23244436372     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000173420.31354.ef     Document Type: Article

References (25)

1. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSII-3: effects of lisinopril and transdermal glyceryl trinitrale singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet. 1994;343:1115-1122.
2. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction the CAPRICORN randomized trial. Lancet. 2001;357:1385-1390.
3. Pfeffer MA, McMurray JJV, Velazguez EJ, Rouleau JI, Kober L, Maggioni AP, Solomon SD, Swedberg K, Werf FV, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, caplopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
4. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation. 1999;100:2093-2099.
5. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens. 1992;10:1111-1114.
6. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Imura H. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87:464-469.
7. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
8. Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R. Prognostic evaluation of neurohormonal plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 2001;38:436-442.
9. Troughton RW, Frampton CM, Tandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
10. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246-253.
11. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura M, Mukoyama M, Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993;88:82-91.
12. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilson DW, Sundsfjord JA, Dickstein K. Plasma brain natriuretic peptides as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation. 1996;93:1963-1969.
13. Izumi T, Saito Y, Kishimoto I, Harada M, Kuwahara K, Hamanaka I, Takahashi N, Kawakami R, Li Y, Takemura G, Fujiwara H, Garbers DL, Mochizuki S, Nakao K. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-κB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest. 2001;108:203-213.
14. Lopez, MJ, Wong SKF, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DJ, Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378:65-68.
15. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res. 1979;44:503-512.
16. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K. Guanylyl cyclase-A inhibits angiotensin II type 1a receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation. 2002;106:1722-1728.
17. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A. 1997;94:14730-14735.
18. Kishimoto I, Dubois SK, Garbers DL. The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion. Proc Natl Acad Sci U S A. 1996;93:6215-6219.
19. Ito T, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, Mizuno Y, Yamamuro M, Harada M, Saito Y, Nakao K, Kurihara H, Yasue H, Ogawa H. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation. 2003;107:807-810.
20. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JH, Smithies O, Rockman HA, Maeda N. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest. 2001;107:975-984.
21. Klinger JR, Warburton RR, Pietras L, Oliver P, Fox J, Smithies O, Hill NS. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2002;282:H58-H65.
22. Holtwick R, Eickels MV, Skryabin BV, Baba HA, Bubikat A, Begrow F, Secneider MD, Garbers DL, Kuhn M. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest. 2003;111:1399-1407.
23. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kanagawa K, Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension. 2000;35:19-24.
24. Hayashi M, Tsutamoto T, Wada A, Maeda A, Mabuchi N, Tsutsui T, Horie H, Ohnishi M, Kinoshita M. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37:1820-1826.
25. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K. Functional deletion mutation of the 5′-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res. 2000;86:841-845.